Market Research Logo

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2015

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2015’, provides an overview of the Chemotherapy Induced Peripheral Neuropathy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Peripheral Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Peripheral Neuropathy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Chemotherapy Induced Peripheral Neuropathy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Chemotherapy Induced Peripheral Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Chemotherapy Induced Peripheral Neuropathy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Chemotherapy Induced Peripheral Neuropathy Overview
Therapeutics Development
Pipeline Products for Chemotherapy Induced Peripheral Neuropathy - Overview
Pipeline Products for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis
Chemotherapy Induced Peripheral Neuropathy - Therapeutics under Development by Companies
Chemotherapy Induced Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes
Chemotherapy Induced Peripheral Neuropathy - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Chemotherapy Induced Peripheral Neuropathy - Products under Development by Companies
Chemotherapy Induced Peripheral Neuropathy - Products under Investigation by Universities/Institutes
Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development
DARA BioSciences, Inc.
DermaXon, LLC
Eisai Co., Ltd.
Immune Pharmaceuticals Inc.
Laboratorios Del Dr. Esteve S.A.
MAKScientific, LLC
Mertiva AB
Panacea Pharmaceuticals, Inc.
PharmatrophiX, Inc.
Spectrum Pharmaceuticals, Inc.
Spinifex Pharmaceuticals Pty Limited
Virobay Inc.
Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(amitriptyline + ketamine hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL-309 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AM-1710 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Pain - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DX-0332 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E-2072 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E-52862 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EMA-401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ketoprofen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KRN-5500 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LM11A-31 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PAN-811 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PGN-703 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SPI-205 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VBY-036 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chemotherapy Induced Peripheral Neuropathy - Recent Pipeline Updates
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects
Chemotherapy Induced Peripheral Neuropathy - Discontinued Products
Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones
Featured News & Press Releases
Feb 25, 2014: DARA BioSciences' KRN5500 Receives Orphan Drug Designation From FDA
Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program
Apr 10, 2012: EpiCept's AmiKet Receives Fast Track Designation From FDA
Mar 28, 2012: Allon Receives US Patent Covering Use Of Its Neuroprotective Technology Platform
Feb 07, 2012: EpiCept Files For AmiKet Fast Track Designation
Dec 23, 2011: EpiCept Receives FDA Permission To Initiate AmiKet Phase III Clinical Development
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2015
Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Chemotherapy Induced Peripheral Neuropathy - Pipeline by DARA BioSciences, Inc., H2 2015
Chemotherapy Induced Peripheral Neuropathy - Pipeline by DermaXon, LLC, H2 2015
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Eisai Co., Ltd., H2 2015
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc., H2 2015
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2015
Chemotherapy Induced Peripheral Neuropathy - Pipeline by MAKScientific, LLC, H2 2015
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Mertiva AB, H2 2015
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Panacea Pharmaceuticals, Inc., H2 2015
Chemotherapy Induced Peripheral Neuropathy - Pipeline by PharmatrophiX, Inc., H2 2015
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Spinifex Pharmaceuticals Pty Limited, H2 2015
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Virobay Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Chemotherapy Induced Peripheral Neuropathy Therapeutics - Recent Pipeline Updates, H2 2015
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H2 2015
Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2015
Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report